Last reviewed · How we verify
NCT03726866
A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects
Phase 1 trial testing Sequence 1 in Dyslipidemias in 30 participants. Status unknown.
15 January 2019
Quick facts
| Lead sponsor | Chong Kun Dang Pharmaceutical |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 31 August 2018 |
| Primary completion | 15 January 2019 |
| Estimated completion | 15 January 2019 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Sequence 1 — full drug profile →
- Sequence 2 — full drug profile →
- Sequence 3
- Sequence 4 — full drug profile →
- Sequence 5 — full drug profile →
- Sequence 6 — full drug profile →
Conditions studied
- Dyslipidemias — all drugs for Dyslipidemias →
- Hypertension — all drugs for Hypertension →
Sponsor
Chong Kun Dang Pharmaceutical — full company profile →
Who can join
Adults 19 to 40, any sex, with Dyslipidemias or Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate pharmacokinetic properties and drug interactions between D326 and D337 co-administered groups, the CKD-828 alone and the total co-administered groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03726866
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sequence 1
Trials testing the same drug.
- NCT06584240 — A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity · Phase 1, PHASE2 · completed
Other recruiting trials for Dyslipidemias
Currently open trials in the same condition.
- NCT07308314 — Taining Golden Lake Comprehensive Chronic Disease Management Initiative · recruiting
- NCT06526273 — PILI 'Āina Household · NA · recruiting
- NCT06797401 — Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia · Phase 2 · recruiting
- NCT06380322 — Military Health and Nutrition Examination Study · recruiting
- NCT06183307 — Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia · NA · recruiting
Other Chong Kun Dang Pharmaceutical trials
Trials by the same sponsor.
- NCT07404735 — A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 · Phase 1 · not yet recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
- NCT07258745 — Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-appro · Phase 1 · recruiting
- NCT07304726 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers · Phase 1 · completed
- NCT07304700 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03726866 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chong Kun Dang Pharmaceutical
- Last refreshed: 1 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03726866.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing